Higher age and higher maintenance doses are risk factors for pulmonary toxicity in Japanese patients on low-dose amiodarone, suggesting a need for further dose reduction.
Answers are grounded in this paper and cite their sources.
Low-dose amiodarone pulmonary toxicity risk rises with age and dose; leaves open optimal regimens for prospective trials.
Even at low dose, amiodarone shows substantial pulmonary toxicity. Higher age and higher maintenance dose are risk factors. Further decreasing the maintenance dose of amiodarone should be considered in order to reduce the incidence of pulmonary toxicity, at least in Japanese patients.
No takes yet. Share an insight, caveat, or question.
Yamada et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: